Health

Results: 673-684 of 9180

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

PR Newswire associated0

Advaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved

How GMA with MOVIVA® works

MOVIVA® launch spotlight at ESGE Days 2026

SciBase: Interim report

PR Newswire associated0

BioPhorum Acquires PharmaX Solutions, Empowering The Life Sciences Industry to Turn Best Practice Insight into Operational Solutions at Scale

Photocure ASA: Results for the first quarter of 2026

Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it is managed by balloon dilatation or DVIU Urethrotomy. The open urethrotomy wound after dilatation or DVIU has to heal from the edges of the wound, which may take a longer time. In BEES-HAUS cell therapy, the cell transplant having proven successful engraftment, covering the urethrotomy wound, yielding clinical safety and efficacy may be considered to be included in the treatment guidelines after validation. Its simplified version, the BHES-HAUS (Buccal epithelium Hashed and Encapsulated in Scaffold—Hybrid Approach to Urethral Stricture) accomplished in one-go without need for cell culture in a lab, works on similar principles. After long term follow-up, BHES-HAUS minimally invasive approach may be worth combining with DVIU and balloon dilatation, as it may be able to provide longer duration of recurrence-free, good quality of life without need for intermittent self-catheterization.

Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 2026

PR Newswire associated0

/C O R R E C T I O N -- Elsevier Limited/